ArriVent Biopharma focuses on accelerating the global development of innovative biopharmaceutical products with an initial focus in oncology. Its lead product candidate, furmonertinib, is a highly brain-penetrant, mutant-specific EGFR kinase inhibitor. The company uses a deep and global network to access drug candidates at various development stages, including those from China and other emerging biotech hubs. ArriVent pursues strategic collaborations to globalize medicines for patients with unmet medical need across a broad range of diseases. Following a $155M Series B, the company intends to use proceeds to support pivotal Phase 3 and additional studies of furmonertinib and to fund future pipeline expansion. The company is led by CEO Bing Yao and added board appointees in conjunction with the financing. ArriVent Biopharma identifies therapeutics developed in China and other emerging biotech hubs and in-licenses ex-China rights to develop them for U.S., EU and other markets. Its current pipeline anchor is furmonertinib, an EGFR TKI recently approved in China for NSCLC, which ArriVent secured ex-China rights to from Allist Pharma. The company plans to submit an IND this year to study furmonertinib in EGFR-mutant NSCLC patients in the U.S. ArriVent aims to repeat the furmonertinib blueprint by seeking additional validated assets to expand its pipeline. Leadership includes CEO Bing Yao and co-founder/chief medical officer Stuart Lutzker, who will work to gather the clinical data needed for Western development. Financially, ArriVent has secured up to $150 million to fund these activities, including $90 million upfront and up to $60 million contingent on milestones.

Total raised

$305M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2023